19 results on '"Mayo, Martha R."'
Search Results
2. Effect of patiromer on reducing serum potassium and preventing recurrent hyperkalaemia in patients with heart failure and chronic kidney disease on RAAS inhibitors
3. Patiromer to Enable Spironolactone in Patients with Resistant Hypertension and CKD (AMBER)
4. Effect of Patiromer on Serum Potassium Level in Patients With Hyperkalemia and Diabetic Kidney Disease: The AMETHYST-DN Randomized Clinical Trial
5. Patiromer in Patients with Kidney Disease and Hyperkalemia Receiving RAAS Inhibitors
6. PATIROMER VS PLACEBO TO ENABLE SPIRONOLACTONE IN PATIENTS WITH RESISTANT HYPERTENSION AND CKD: ANALYSIS ACCORDING TO PATIENT SEX (AMBER TRIAL)
7. Patiromer and Spironolactone in Resistant Hypertension and Advanced CKD: Analysis of the Randomized AMBER Trial
8. Peginesatide for Anemia in Patients with Chronic Kidney Disease Not Receiving Dialysis
9. Peginesatide in Patients with Anemia Undergoing Hemodialysis
10. Patiromer versus placebo to enable spironolactone use in patients with resistant hypertension and chronic kidney disease (AMBER): results in the pre‐specified subgroup with heart failure
11. Patiromer vs. Placebo to Enable Spironolactone in Patients with Resistant Hypertension and Chronic Kidney Disease (AMBER): Results in Prespecified Subgroups
12. Patiromer versus placebo to enable spironolactone use in patients with resistant hypertension and chronic kidney disease (AMBER): a phase 2, randomised, double-blind, placebo-controlled trial
13. Patiromer to Enable Spironolactone Use in the Treatment of Patients with Resistant Hypertension and Chronic Kidney Disease: Rationale and Design of the AMBER Study.
14. Long-term effects of patiromer for hyperkalaemia treatment in patients with mild heart failure and diabetic nephropathy on angiotensin-converting enzymes/angiotensin receptor blockers: results from AMETHYST-DN
15. Effectiveness of patiromer in the treatment of hyperkalemia in chronic kidney disease patients with hypertension on diuretics
16. Evaluation of the Potential for Drug Interactions With Patiromer in Healthy Volunteers
17. OS 19-03 TREATMENT WITH PATIROMER RESULTED IN DECREASES IN ALDOSTERONE IN PATIENTS WITH CHRONIC KIDNEY DISEASE AND HYPERKALEMIA ON RAAS INHIBITORS
18. Treatment with patiromer decreases aldosterone in patients with chronic kidney disease and hyperkalemia on renin-angiotensin system inhibitors
19. 1118-P: Effect of Patiromer in Patients 75 Years or Older with Diabetic Kidney Disease and Hyperkalemia Receiving a RAAS Inhibitor.
Catalog
Books, media, physical & digital resources
Discovery Service for Jio Institute Digital Library
For full access to our library's resources, please sign in.